XellSmart Reports Initial Data for Parkinson's Cell Therapy
XellSmart presented Phase 1 clinical data for its off-the-shelf Parkinson's disease cell therapy at a recent medical congress. The company also announced the completion of patient enrollment for the blinded Phase 2 portion of the study.
SEOUL, South Korea and SHANGHAI – XellSmart unveiled new clinical data for its off-the-shelf cell therapy designed for Parkinson's Disease. The company presented these findings at the International Congress of Parkinson's Disease and Movement Disorders (MDS).
Researchers shared information from the Phase 1 clinical trial of the therapy. Additionally, XellSmart announced the completion of blinded enrollment for the Phase 2 portion of the study.
The therapy represents an allogeneic, or off-the-shelf, treatment. This means doctors can administer the treatment without needing patient-specific cell donations.
XellSmart plans to continue monitoring patients enrolled in the clinical trials as the study progresses.
Related Topics
Article Ratings
How do you feel about this story?
National Desk
Sign in to follow this author from their profile.
Discussion (0)
Join the Conversation
Join the conversation
Sign in to share your thoughts, reply to readers, and like comments.
No comments yet. Be the first to comment!